Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

story of the week
Published in Renal Cell Carcinoma

Journal Scan / Research · August 01, 2022

HRQoL in Patients With Advanced RCC Treated With Pembrolizumab Plus Axitinib vs Sunitinib Monotherapy

European Urology


Additional Info

Disclosure statements are available on the authors' profiles:

European Urology
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma
Eur Urol 2022 Jul 14;[EPub Ahead of Print], J Bedke, BI Rini, ER Plimack, V Stus, R Gafanov, T Waddell, D Nosov, F Pouliot, D Soulières, B Melichar, I Vynnychenko, SJ Azevedo, D Borchiellini, RS McDermott, S Tamada, AM Nguyen, S Wan, RF Perini, L Rhoda Molife, MB Atkins, T Powles

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading